David Bunka News Today

With alternative technologies available, we should be seeking antibody alternatives that avoid the unnecessary use of animals in research, urges Dr Davi...

Aptamer Group PLC on Thursday announced a cost-cutting drive as it aims to break even within two years. The York-based biotech firm that makes synthetic antibodies capable of binding to targets such...

The former chief executive and chairman of Aptamer Group have returned to take control of the York-based biotech company after months of turmoil.

Sale process ends as AIM-listed group's board resigns

Oligonucleotide affinity ligands developer Aptamer Group has developed a panel of binders to a novel Alzheimer’s disease biomarker, patented by partners at Neuro-Bio, following the demonstration of performance in specifically binding to the target biomarker and functionality in a nasal mucous matrix. Click to read more...

Investegate announcements from Aptamer Group PLC, Notice of Interim Results

UK firm links with up global drug firms to make synthetic antibodies capable of binding to targets such as tumour cells

Investegate announcements from Aptamer Group PLC, Investor Webinar

Investegate announcements from Aptamer Group PLC, Notice of Full Year Results

A THRIVING York bio-technology firm will shortly move into new offices that are three times the size of its current base.